Rybelsus vs Victoza
A side-by-side look at two diabetes medications advertised on TV. Informational only — not medical advice.
| US Rybelsus | US Victoza | |
|---|---|---|
| Generic name | semaglutide | liraglutide |
| Drug class | GLP-1 Receptor Agonist | GLP-1 Receptor Agonist |
| Treats | Type 2 diabetes | Type 2 diabetes |
| Category | Diabetes | Diabetes |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| Year approved | 2019 | 2010 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $180M | — |
| Common side effects | Nausea, Abdominal pain, Diarrhea, Decreased appetite | Nausea, Diarrhea, Headache, Risk of thyroid C-cell tumors (boxed warning) |
Frequently asked questions
Is Rybelsus or Victoza better?
Neither is universally "better." Rybelsus (semaglutide) and Victoza (liraglutide) are both used for diabetes, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Rybelsus and Victoza?
Rybelsus is a GLP-1 Receptor Agonist made by Novo Nordisk, while Victoza is a GLP-1 Receptor Agonist made by Novo Nordisk. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Rybelsus has the larger estimated TV advertising budget of the two.